Record entry · Auto
Roche
The Swiss pharmaceutical giant — the world's largest oncology drugmaker and owner of Genentech.
Why this name is on the record
Roche was added automatically on 5 Oct 2026 after 106 mentions across 38 sources over 31 days. 30% of that coverage came from a single subject area.
“Nigerian drugmaker Fidson selected to manufacture generic influenza antiviral under global licence”
“Shippers urged to check routings as alliances redraw Asia–S America trade”
“Roche launches simultaneous screening test for SMA, SCID and SCD”
“STAT+: Roche expands its Boston footprint with new research center”
“Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival”
“Fierce Pharma Asia—Roche, GSK, Novartis billion-dollar deals; More MFN sign-ups; Akeso’s OS win”
For developers
GET https://sigb.ai/api/registry?slug=roche
{
"slug": "roche",
"state": "active",
"detail": {
"state": "active",
"source": "ontology",
"label": "roche",
"promotedAt": "2026-10-05",
"category": "auto",
"evidence": {
"mentions": 106,
"sources": 38,
"days": 31,
"concentration": 0.302,
"standAloneShare": 0.816
}
}
}The record behind this page, as data. The live response also carries the registry date and version.
The coverage behind it
- 4 Oct 2026
Premium Times Nigeria
Nigerian drugmaker Fidson selected to manufacture generic influenza antiviral under global licence
“Nigerian drugmaker Fidson selected to manufacture generic influenza antiviral under global licence”
- 2 Oct 2026
The Loadstar
Shippers urged to check routings as alliances redraw Asia–S America trade
“Shippers urged to check routings as alliances redraw Asia–S America trade”
- 1 Oct 2026
Fierce Biotech
Roche launches simultaneous screening test for SMA, SCID and SCD
“Roche launches simultaneous screening test for SMA, SCID and SCD”
- 19 Sept 2026
STAT News — All Content
STAT+: Roche expands its Boston footprint with new research center
“STAT+: Roche expands its Boston footprint with new research center”
- 14 Sept 2026
Fierce Biotech
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
“Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival”
- 3 Sept 2026
Fierce Pharma
Fierce Pharma Asia—Roche, GSK, Novartis billion-dollar deals; More MFN sign-ups; Akeso’s OS win
“Fierce Pharma Asia—Roche, GSK, Novartis billion-dollar deals; More MFN sign-ups; Akeso’s OS win”
No trend and no market price are shown because neither has been measured for Roche yet. Informational only, not advice. As of 5 Oct 2026.